Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 119,700 shares, an increase of 93.4% from the February 13th total of 61,900 shares. Currently, 6.5% of the shares of the stock are sold short. Based on an average daily volume of 4,130,000 shares, the short-interest ratio is presently 0.0 days.

Cyclerion Therapeutics Stock Up 4.5 %

Shares of CYCN stock traded up $0.11 during trading hours on Friday, hitting $2.58. 1,628 shares of the company’s stock were exchanged, compared to its average volume of 2,412,699. Cyclerion Therapeutics has a fifty-two week low of $1.27 and a fifty-two week high of $9.47. The firm has a market cap of $6.99 million, a P/E ratio of -2.11 and a beta of 2.09. The firm has a 50 day moving average of $3.06 and a two-hundred day moving average of $2.91.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its earnings results on Tuesday, March 4th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $1.81 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Renaissance Technologies LLC purchased a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned about 0.39% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.